domingo, 2 de diciembre de 2012

PFIZER: Nace una marca...Xeljanz.Ufff!

Es Xel Ha...? 


 Es Xeljanz...


Pharmaceutical preparations for the treatment of immunological and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations, namely, dermatological preparations

Pfizer won approval for pill Xeljanz (tofacitinib), a new approach to treating rheumatoid arthritis. The firm hopes the drug can carve out a niche by pushing back physicians' use of biologics and winning over the untreated. (…)
"We expect physicians to ultimately use the drug in a wide group of patients, but it will initially likely be used in patients who don't respond adequately to biologics," a group comprising between 20%-40% of patients on biologics, wrote Credit-Suisse analyst Catherine Arnold in an investor note yesterday.
Arnold models $2.6 billion in peak sales by 2020. "We believe the drug has the potential to 'steal' a modest share of the ~$23 Bn worldwide market, and at the same time help trigger market expansion," she added.
Xeljanz could prove disruptive to Abbott's Humira, Amgen/Pfizer's Enbrel, and to UCB's Cimzia, Arnold wrote, while J&J/Merck's Remicade and Sinponi and Bristol-Myer Squibb's Orencia will feel less of a threat. (Más)

Ufff, menuda marca...!
Publicar un comentario